Insulet (NASDAQ:PODD) Given New $360.00 Price Target at Jefferies Financial Group

Insulet (NASDAQ:PODD) had its price objective reduced by Jefferies Financial Group from $400.00 to $360.00 in a report released on Thursday,MarketScreener reports.

Several other research analysts have also recently weighed in on the company. Sanford C. Bernstein decreased their price target on Insulet from $330.00 to $200.00 and set an “outperform” rating for the company in a research note on Thursday. Weiss Ratings upgraded Insulet from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, May 1st. Oppenheimer decreased their price target on Insulet from $300.00 to $210.00 and set an “outperform” rating for the company in a research note on Thursday. Citigroup decreased their price target on Insulet from $230.00 to $175.00 in a research note on Thursday. Finally, Canaccord Genuity Group decreased their price target on Insulet from $450.00 to $435.00 and set a “buy” rating for the company in a research note on Wednesday, February 18th. Eighteen research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $257.09.

Insulet Stock Up 6.0%

Shares of NASDAQ:PODD opened at $160.40 on Thursday. The stock has a fifty day simple moving average of $211.22 and a two-hundred day simple moving average of $263.85. The stock has a market capitalization of $11.11 billion, a price-to-earnings ratio of 37.30, a PEG ratio of 0.89 and a beta of 1.20. Insulet has a 12-month low of $148.30 and a 12-month high of $354.88. The company has a current ratio of 2.49, a quick ratio of 2.15 and a debt-to-equity ratio of 0.71.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. The business had revenue of $761.70 million during the quarter, compared to analysts’ expectations of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The firm’s quarterly revenue was up 33.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, research analysts anticipate that Insulet will post 6.27 earnings per share for the current fiscal year.

Insider Activity at Insulet

In other news, Director Michael R. Minogue acquired 2,030 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The stock was bought at an average price of $246.23 per share, with a total value of $499,846.90. Following the completion of the acquisition, the director directly owned 17,483 shares of the company’s stock, valued at approximately $4,304,839.09. The trade was a 13.14% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.36% of the stock is owned by insiders.

Institutional Trading of Insulet

Large investors have recently modified their holdings of the company. Larson Financial Group LLC grew its holdings in shares of Insulet by 114.6% in the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 47 shares during the period. University of Texas Texas AM Investment Management Co. bought a new stake in shares of Insulet in the fourth quarter worth $26,000. Elyxium Wealth LLC bought a new stake in shares of Insulet in the fourth quarter worth $28,000. DV Equities LLC bought a new stake in shares of Insulet in the fourth quarter worth $28,000. Finally, MV Capital Management Inc. bought a new stake in shares of Insulet in the fourth quarter worth $29,000.

More Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Q1 beat and guidance raise — Insulet reported Q1 revenue of $761.7M (+33.9% YoY) and adjusted EPS $1.42, topping estimates; management raised FY2026 constant?currency revenue growth to 21%–23% and reiterated margin expansion, which helped lift sentiment. Business Wire: Q1 Results
• Positive Sentiment: Omnipod international momentum — Management highlighted sharp international Omnipod revenue growth and continued geographic expansion (including new Middle East Omnipod 5 launches), supporting growth durability beyond the U.S. market. Reuters: Growth/Forecast
• Positive Sentiment: Profitability and insider buying — Adjusted operating margin expanded and EPS beat consensus; several insiders (including the CEO) bought shares recently, which can signal management confidence. QuiverQuant: Earnings analysis & insider activity
• Neutral Sentiment: Analyst ratings still mixed — Several firms reiterated buy/overweight stances even as they trimmed targets; median analyst targets remain well above current levels, leaving upside claims but greater dispersion in near?term expectations. QuiverQuant: Analyst moves & targets
• Negative Sentiment: Widespread price?target cuts — Multiple brokers lowered targets (Piper Sandler, BofA/JPMorgan/others), reflecting model resets after the print; that put near?term pressure on sentiment despite the beat. MarketScreener: Piper Sandler target cut

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.